Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...
Finanznachrichten3h
Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
Ms. Ricciardi concluded: "In addition to the substantial progress we have made with CT1812 in Alzheimer's disease, we expect to report top-line results from our Phase 2 SHIMMER study in ...
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort ...
After Tampa Bay’s two hurricanes, uncertainty, trauma and one lost cat
As the days stretch into months after Tampa Bay’s most destructive hurricane season in a century, the lonely slog of recovery ...